Skip to Content

Are you based in North America? If yes, switch to our North American website →

IGH/CCND1 Translocation, Dual Fusion

Applications
haematopathology
Catalogue Numbers
LPS 031 (10 tests)
LPS 031-S (5 tests)

Although translocations involving IGH and CCND1 (BCL1) were initially reported in B-CLL patients, the rearrangement is now considered to be a hallmark of mantle cell lymphoma (MCL).

Reciprocal translocations involving the IGH and CCND1 (previously known as BCL1) loci, t(11;14)(q13;q32), were frequently reported in B-CLL patients1. The involvement of the CCND1 (Cyclin D1) gene was initially reported from a cloning study looking at the breakpoints of the translocation. However, it is likely that the initial diagnosis on the samples used for the study should have been MCL. The IGH/CCND1 probe for detection of t(11;14) has been recommended by the British Committee for Standards in Haematology to enable atypical B-CLL patients to be distinguished from possible MCL patients2.

References

1. Brizard et al., Leuk Lymphoma 1997;25(5-6):539-43

2. Parker et al., Best Practice in Lymphoma Diagnosis and Reporting; Specific disease appendix 2010, p5

Microscope Images

IGH CCND1 Translocation Dual Fusion magnified
Area of Interest*
Lymphoma

Disclaimer

This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples, or formalin-fixed paraffin-embedded (FFPE) tissues.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.